You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Clobazam - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for clobazam and what is the scope of freedom to operate?

Clobazam is the generic ingredient in three branded drugs marketed by Otter Pharms, Accord Hlthcare, Alkem Labs Ltd, Amneal, Aurobindo Pharma Ltd, Bionpharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Lupin Ltd, Norvium Bioscience, Taro, Teva Pharms Usa, Upsher Smith Labs, Vistapharm, Lundbeck Pharms Llc, Amneal Pharms Co, Anda Repository, Apotex, Breckenridge, Micro Labs, MSN, Piramal, and Zydus Pharms, and is included in thirty-four NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Clobazam has one hundred and sixty-eight patent family members in nineteen countries.

There are ten drug master file entries for clobazam. Twenty-three suppliers are listed for this compound.

Drug Prices for clobazam

See drug prices for clobazam

Recent Clinical Trials for clobazam

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Dr Cipto Mangunkusumo General HospitalPhase 4
Wayne State UniversityPhase 4
Jazz PharmaceuticalsPhase 3

See all clobazam clinical trials

Pharmacology for clobazam
Anatomical Therapeutic Chemical (ATC) Classes for clobazam

US Patents and Regulatory Information for clobazam

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anda Repository CLOBAZAM clobazam TABLET;ORAL 211959-002 Dec 9, 2020 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Upsher Smith Labs CLOBAZAM clobazam TABLET;ORAL 209687-001 Oct 22, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Ltd CLOBAZAM clobazam SUSPENSION;ORAL 214404-001 Mar 24, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for clobazam

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-003 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-001 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
Otter Pharms SYMPAZAN clobazam FILM;ORAL 210833-002 Nov 1, 2018 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for clobazam

Country Patent Number Title Estimated Expiration
Mexico 2015013184 COMPOSICIONES DE PELICULAS SUBLINGUAL Y BUCAL. (SUBLINGUAL AND BUCCAL FILM COMPOSITIONS.) ⤷  Sign Up
Russian Federation 2015143647 ПЛЕНОЧНЫЕ КОМПОЗИЦИИ ДЛЯ СУБЛИНГВАЛЬНОГО И БУККАЛЬНОГО ВВЕДЕНИЯ ⤷  Sign Up
European Patent Office 2335921 Films multicouches (Multi-layer films) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.